Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc (BEAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) GlobeNewswire - Thu May 29, 3:01PM CDT

BEAM : 15.89 (-2.63%)
Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress GlobeNewswire - Wed May 14, 8:30AM CDT

BEAM : 15.89 (-2.63%)
Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference GlobeNewswire - Tue May 13, 6:00AM CDT

BEAM : 15.89 (-2.63%)
Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) GlobeNewswire - Mon May 12, 3:01PM CDT

BEAM : 15.89 (-2.63%)
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut Zacks Investment Research - Fri May 9, 8:24AM CDT

Iovance Biotherapeutics, Inc. IOVA incurred a first-quarter 2025 loss of 36 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. In the year-ago quarter, the company reported...

BEAM : 15.89 (-2.63%)
IOVA : 1.7550 (-4.10%)
ELEV : 0.3024 (-1.21%)
ADPT : 9.51 (+2.15%)
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y Zacks Investment Research - Thu May 8, 12:24PM CDT

Amarin Corporation AMRN reported a loss of 4 cents per share for the first quarter of 2025, which was significantly narrower than the Zacks Consensus Estimate of a loss of $1.12. The company had reported...

BEAM : 15.89 (-2.63%)
AMRN : 11.38 (-2.61%)
ANIP : 58.49 (+0.39%)
NTLA : 7.07 (-5.10%)
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates
BEAM Stock Down 19% as Q1 Earnings & Revenues Miss Estimates Zacks Investment Research - Wed May 7, 9:12AM CDT

Beam Therapeutics BEAM reported a loss of $1.24 per share for the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of $1.11. The company had reported a loss of $1.21 per...

BEAM : 15.89 (-2.63%)
IMCR : 35.02 (-0.06%)
ANIP : 58.49 (+0.39%)
NTLA : 7.07 (-5.10%)
Why Beam Therapeutics Stock Tanked on Tuesday Motley Fool - Tue May 6, 4:05PM CDT

Precision gene-editing company Beam Therapeutics (NASDAQ: BEAM) had a Tuesday to forget on the stock market. Following the release that morning of its latest set of quarterly results, the shares raced...

BEAM : 15.89 (-2.63%)
NFLX : 1,191.52 (+0.56%)
NVDA : 136.56 (-1.89%)
$SPX : 5,906.91 (-0.09%)
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights GlobeNewswire - Tue May 6, 6:00AM CDT

BEAM : 15.89 (-2.63%)
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates Zacks Investment Research - Fri May 2, 11:18AM CDT

Alkermes plc ALKS reported earnings from continuing operations of 13 cents per share for first-quarter 2025, which missed the Zacks Consensus Estimate of 28 cents. The company had reported earnings of...

BEAM : 15.89 (-2.63%)
IMCR : 35.02 (-0.06%)
ADMA : 19.77 (-0.40%)
ALKS : 30.70 (+1.49%)

Barchart Exclusives

This Penny Stock Just Doubled on Plans to Become a Bitcoin Miner. Should You Buy It Now? Barchart - 18 minutes ago
Shares of the specialized digital platform company are up a scarcely believable 242% over the past week. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot
OSZAR »